133 related articles for article (PubMed ID: 12218384)
1. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).
Olson DP; Scadden DT; D'Aquila RT; De Pasquale MP
AIDS; 2002 Sep; 16(13):1743-7. PubMed ID: 12218384
[TBL] [Abstract][Full Text] [Related]
2. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
3. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P
Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083
[TBL] [Abstract][Full Text] [Related]
4. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.
Bachmeier CJ; Spitzenberger TJ; Elmquist WF; Miller DW
Pharm Res; 2005 Aug; 22(8):1259-68. PubMed ID: 16078135
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.
Janneh O; Jones E; Chandler B; Owen A; Khoo SH
J Antimicrob Chemother; 2007 Nov; 60(5):987-93. PubMed ID: 17890284
[TBL] [Abstract][Full Text] [Related]
7. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
9. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.
Eilers M; Roy U; Mondal D
Exp Biol Med (Maywood); 2008 Sep; 233(9):1149-60. PubMed ID: 18535159
[TBL] [Abstract][Full Text] [Related]
10. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
11. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
Kim HS; Min YD; Choi CH
Biochem Biophys Res Commun; 2001 Apr; 283(1):64-71. PubMed ID: 11322768
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
13. Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition.
Lucia MB; Savarino A; Straface E; Golotta C; Rastrelli E; Matarrese P; Rutella S; Malorni W; Cauda R
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):257-66. PubMed ID: 16249698
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
Dupuis ML; Tombesi M; Sabatini M; Cianfriglia M
Chemotherapy; 2003 May; 49(1-2):8-16. PubMed ID: 12714803
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Hsu A; Granneman GR; Bertz RJ
Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
[TBL] [Abstract][Full Text] [Related]
16. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.
Zastre JA; Chan GN; Ronaldson PT; Ramaswamy M; Couraud PO; Romero IA; Weksler B; Bendayan M; Bendayan R
J Neurosci Res; 2009 Mar; 87(4):1023-36. PubMed ID: 18855943
[TBL] [Abstract][Full Text] [Related]
18. Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein.
Bousquet L; Pruvost A; Didier N; Farinotti R; Mabondzo A
Eur J Pharm Sci; 2008 Nov; 35(4):247-56. PubMed ID: 18692133
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
Huisman MT; Smit JW; Crommentuyn KM; Zelcer N; Wiltshire HR; Beijnen JH; Schinkel AH
AIDS; 2002 Nov; 16(17):2295-301. PubMed ID: 12441801
[TBL] [Abstract][Full Text] [Related]
20. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Zhang L; Gorset W; Washington CB; Blaschke TF; Kroetz DL; Giacomini KM
Drug Metab Dispos; 2000 Mar; 28(3):329-34. PubMed ID: 10681378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
